new glp-1 receptor agonists Understanding and their impact on drug discovery GLP-1 Receptor Agonists: New Frontiers
Description
[11] Without doctor oversight, lab work, or personalized care, these risks go unchecked
Studies have shown a reduction in major cardiovascular events
Retrieved from Pratama, K
doi: 10.1016/j.bcp.2020.114187, 130 SanfordM
If more pharma companies move to DTC models, self-funded employers will likely need to adapt their benefits strategy to accommodate this shift
Saunders agree it often comes down to individual factors including cost, insurance coverage, availability, and patient tolerability
